On 16 April 2018, orphan designation (EU/3/18/2009) was granted by the European Commission to SOTIO a.s, Czech Republic, for autologous dendritic cells pulsed with killed ovarian cancer cells and matured by TLR3 ligand ex vivo (also known as DCVAC/OvCa) for the treatment of ovarian cancer.
autologous dendritic cells pulsed with killed ovarian cancer cells and matured by TLR3 ligand ex vivo
Treatment of ovarian cancer
|Orphan designation status||
|EU designation number||
|Date of designation||
|August 2022||The sponsor's name was changed from SOTIO a.s. to SCTbio a.s. in August 2022.|
|August 2022||Please note that this product was withdrawn from the Union Register of orphan medicinal products in August 2022 on request of the Sponsor.|
Documents related to this orphan designation evaluation
EU/3/18/2009: Public summary of opinion on orphan designation: Autologous dendritic cells pulsed with killed ovarian cancer cells and matured by TLR3 ligand ex vivo for the treatment of ovarian cancer (PDF/208.29 KB)
First published: 17/05/2018
Last updated: 17/08/2022
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: